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Self-Assembly of Therapeutic Peptide into Stimuli-Responsive 
Clustered Nanohybrids for Cancer-Targeted Therapy
Wangxiao He, Simeng Wang, Jin Yan, Yiping Qu, Liang Jin, Fang Sui, Yujun Li, 
Weiming You, Guang Yang, Qi Yang, Meiju Ji, Yongping Shao, Peter X. Ma,* 
Wuyuan Lu,* and Peng Hou*
Clinical translation of therapeutic peptides, particularly those targeting 
intracellular protein–protein interactions (PPIs), has been hampered by their 
inefficacious cellular internalization in diseased tissue. Therapeutic peptides 
engineered into nanostructures with stable spatial architectures and smart 
disease targeting ability may provide a viable strategy to overcome the phar-
maceutical obstacles of peptides. This study describes a strategy to assemble 
therapeutic peptides into a stable peptide–Au nanohybrid, followed by further 
self-assembling into higher-order nanoclusters with responsiveness to tumor 
micro environment. As a proof of concept, an anticancer peptide termed 
β-catenin/Bcl9 inhibitors is copolymerized with gold ion and assembled into 
a cluster of nanohybrids (pCluster). Through a battery of in vitro and in vivo 
tests, it is demonstrated that pClusters potently inhibit tumor growth and 
metastasis in several animal models through the impairment of the Wnt/β-
catenin pathway, while maintaining a highly favorable biosafety profile. In 
addition, it is also found that pClusters synergize with the PD1/PD-L1 check-
point blockade immunotherapy. This new strategy of peptide delivery will 
likely have a broad impact on the development of peptide-derived therapeutic 
nanomedicine and reinvigorate efforts to discover peptide drugs that target 
intracellular PPIs in a great variety of human diseases, including cancer.
DOI: 10.1002/adfm.201807736
1. Introduction
Intracellular protein–protein interactions 
(PPIs) is a crucial and yet inadequately 
exploited class of therapeutic targets for 
their essential roles in most of cellular 
processes and disease initiation and pro-
gression.[1] Small molecule drugs have 
been demonstrated to be highly suc-
cessful in targeting enzymes, receptors, 
and ion channels for clinical benefits;[2] 
however, they generally failed to target 
PPIs due to their own physicochemical 
limitations.[3] Peptides, on the other hand, 
can potently and specifically inhibit PPIs, 
aided by their large interacting surface of 
diverse topological structure.[4] In spite of 
their prominent advantages over small-
molecule inhibitors in targeting PPIs, 
peptide inhibitors suffer from two major 
pharmacological deficiencies—poor pro-
teolytic stability and low membrane per-
meability, severely limiting their clinical 
use.[5]
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To overcome these pharmacological hurdles of peptides and 
improve their therapeutic efficacy, two general strategies have 
emerged: 1) chemically modifying peptide backbone and/or 
side chains to enhance proteolytic resistance,[6] and 2) cova-
lently or noncovalently loading peptide cargos to drug delivery 
vehicles for promoting cellular uptake.[5] The first strategy 
often entails the use of sidechain-stapled peptides, backbone-
cyclized (circular) peptides, D-peptides, peptoids, beta-peptides, 
or peptide-grafted miniature proteins.[6,7] The second strategy 
is largely manifested by the development of various peptide 
drug carriers, including macromolecule micelles, liposomes, 
and nanomedicine.[5,8] While some success has been achieved 
in developing peptide therapeutics by using these two strate-
gies,[4,5] significant challenges remain with regard to efficient 
and targeted delivery of therapeutic peptides into cells of dis-
eased tissues such as solid tumors.
Nanoparticles are particularly attractive as anticancer peptide 
drug carriers because of their efficient cellular internalization 
and “enhanced permeability and retention (EPR)” properties.[9] 
Among various nanoparticles, gold nanoparticle (AuNP)-based 
nanocarriers have superior merits such as physicochemical sta-
bility, biocompatibility, and universality.[9c,10] Thus, AuNP-based 
therapies have been widely used in clinical trials, and some of 
them have been approved for clinical use.[11] However, current 
chemistries for peptide conjugation and encapsulation by nano-
particles often lead to product aggregation and precipitation in 
aqueous solution, thereby resulting in low drug loading effi-
ciency and failure of delivery.[5,12] Another technical challenge 
is to ensure efficient spatiotemporal release of peptide cargos 
at the disease sites.[4,13] Overall, these technical obstacles, if not 
overcome, will potentially negate therapeutic efficacy and clin-
ical safety of peptide-derived nanomedicine.[13]
B-cell CLL/lymphoma 9 (Bcl9), a transcriptional cofactor 
overexpressed in human cancers, activates the Wnt/β-catenin 
signaling via interacting with β-catenin to facilitate its nuclear 
translocation, thereby promoting tumor progression.[14] Despite 
the critical role of Wnt/β-catenin pathway in tumorigenesis, it 
remains a challenge to therapeutically intervene this pathway 
for clinical benefits because it is also required for the prolif-
eration and differentiation of stem cells.[15] Thus, compounds 
or modalities that target the Wnt/β-catenin pathway with high 
specificity for cancer cells will be of great clinical significance.
Toward these ends, we nanoengineered therapeutic pep-
tides into a stable peptide–Au nanohybrid in which the poly-
meric Au–peptide precursor [Au(I)-S-peptide]n was reduced and 
assembled into a auric-sphere particle with narrow distribution 
at low nanoscales. Notably, the peptides themselves were uti-
lized as one of the building blocks of the drug delivery system, 
thereby greatly improving the loading efficiency. Moreover, to 
endow delivery system with high targeting ability to tumor, Au–
peptide nanohybrid (nanoparticle) was assembled into a tumor 
microenvironment (TME)-responsive nanocluster with switch-
able charge and size. In this proof-of-concept study, we copoly-
merized HAuCl4 and a peptide inhibitor of the β-catenin–Bcl9 
interaction to form Au–peptide nanohybrid that self-assembled 
into higher-order nanoclusters, termed pCluster. The otherwise 
highly stable pCluster was pH responsive and disintegrated 
into nanoparticles only in the acidic TME, thereby leading to 
efficient and tumor-specific cellular uptake of peptide cargos. 
pCluster potently inhibited not only the growth of various 
cancer cell lines in vitro via blocking Wnt pathway, but also 
suppressed tumor growth and metastasis, and synergized with 
PD1/PD-L1 checkpoint blockade immunotherapy in animal 
models. Importantly, it maintained a highly favorable biosafety 
profile. This viable strategy reported here will enable us to 
develop a class of peptide-derived nanomedicines for cancer 
therapy, and likely reinvigorate peptide drug discovery efforts 
for a great variety of diseases including cancer.
2. Results
2.1. Design of Therapeutic Peptides Targeting 
the Wnt/β-catenin Signaling
β-catenin, the primary signal transducer in the Wnt pathway, 
is important for embryonic development, tumorigenesis, and 
tumor immunology.[16] The dysregulation of the Wnt sign-
aling is considered as a major driving force in the progression 
of many diseases including malignancies.[17] During tumo-
rigenesis, β-catenin interacts with a cofactor Bcl9, shuttling it 
into nucleus to activate its downstream targets.[18] Thus, the 
development of β-catenin/Bcl9 inhibitors (BBIs) is attractive 
for cancer therapy. As the complete and detailed structure of 
β-catenin/Bcl9 complex provided in Figure S1A (Supporting 
Information), three hydrophobic and two charged residues in 
a short peptide termed Bcl9 can interact with a hydrophobic 
groove in β-catenin.[19] This helix consequently has great poten-
tial to be used as a BBI to block the activity of the Wnt sign-
aling (Figure S1A, Supporting Information). To prove this, 
we synthesized the BBI (351–357Bcl9), as shown in Figure S1B 
(Supporting Information), and found that it effectively binds to 
β-catenin with an affinity value of ≈1 × 10−6 m (Figure S1C,D, 
Supporting Information). In addition, using fluorescence 
polarization-based competitive binding assay, we demonstrated 
that the BBI dramatically competed with Bcl9 to bind β-catenin 
(Figure S1E, Supporting Information). Linking to a cell-pene-
trating peptide (RRRRRRRR, named R8), BBI-R8 exhibited 
strong ability to inhibit the proliferation of a hyperactivated-
Wnt-signaling cell line Hep3B (Figure S1F, Supporting Infor-
mation). However, the BBI alone almost did not affect cell 
proliferation (Figure S1F, Supporting Information), which is 
presumably attributed to the membrane impenetrability and 
biologically instability of peptides.[5,20] Collectively, these results 
indicate that BBI is capable of suppressing the proliferation of 
cancer cells through blocking the interaction between Bcl9 and 
β-catenin. Therefore, the BBI peptide may be an ideal example 
to synthesize cytostatic nanoclusters for cancer therapy.
2.2. Preparation of TME-Responsive pCluster
pClusters were prepared by a three step “one pot” reac-
tion, which proceeds in good yield under mild conditions. 
In details, 1) the flavescent Au3+ was reduced by the thiol in 
BBI-SH to form a polymeric structure of [BBI-S-Au(I)]n, termed 
p(BBI-SH-Au1+); and then, 2) p(BBI-S-Au1+) was reduced to a 
polymeric Au–peptide nanoparticle (pParticle) as described 
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previously;[21] finally, 3) a cationic polymer poly-L-lysine (PLL) 
was added to trigger the self-assembly of pParticle into the mas-
sive pCluster (Figures 1 and 2A).
After step (1), structural characterization was attempted by 
performing transmission electron microscopy (TEM) image, in 
which the p(BBI-S-Au1+) presented an irregular amorphous form 
under 5 nm (Figure 2B). The formation of polymeric structure 
was further confirmed by the fourier transform infrared spectra 
(FTIR), and all absorption peaks of free thiol in BBI-SH spectros-
copy disappeared in the p(BBI-S-Au1+) spectroscopy (Figure 2C), 
indicating that Au+1 ions were bridged by the thiolate sulfur atom 
of BBI-SH with a coordination number of 2. Meanwhile, mole-
cular weight of the p(BBI-S-Au1+) was systematically investigated 
by the Mark–Houwink–Sakurada method[22] (Figure 2D) and 
electrospray ionization mass spectrometry (ESI-MS) (Figure 2E), 
and several species with masses from 50 K ([BBI-S-Au+]18) to 
80 K ([BBI-S-Au+]23) were obtained through the above methods.
During step (2), the solution containing carnosic acid (CA) 
and ascorbic acid (VC) decomposed the polymeric structure to 
form the ≈6 nm Au–peptide nanoparticle with a narrow size 
distribution, termed pParticles (Figure 2F and Figure S2A, Sup-
porting Information). To confirm that the BBI-SH was cova-
lently coalesced into the nanoparticle rather than adsorbed on 
the surface, pParticles were solved into 75% acetonitrile (ACN) 
or 8 m GuHCL, respectively, both of which had strong solubility 
of peptides and could elute the peptides from the solid particles. 
As shown in Figure 1G, no peptide was found in the eluant of 
75% ACN or 8 m GuHCl, while dithiothreitol (DTT), a strong 
reductant, triggered the release of BBI from pParticle. These 
data indicate that peptides are covalently bonded to nanoparticles 
rather than adsorbed on the surface. To further verify it, the TEM 
image of the pParticles solved in the DTT solution (10 × 10−3 m in 
phosphate buffered saline (PBS) pH 6.5) were taken (Figure S3A, 
Supporting Information), in which the decomposed pParticles 
showed out-of-shaped low-density shadow like the TEM image 
of free BBI-Sh and CA (Figure S3B, Supporting Information), 
other than the granuliform Au particle. Taken together, these 
results demonstrate that pParticle is a uniform spheroidal auric–
peptide nanohybrid with narrow size distribution. To prove that 
the bioactivity of BBI can be maintained after the polymeriza-
tion, a BBI-free homologous nanohybrid, termed CtrlpParticle, 
was prepared to compare its antitumor activity with pParticle. 
As shown in Figure S2B (Supporting Information), pParticle 
showed stronger in vitro antitumor activity than CtrlpParticle, fur-
ther supporting antitumor bioactivity of BBI.
To endow nanoparticles with high targeting ability to 
tumor, pParticles were assembled into a size-switchable and 
pH- sensitive nanocluster (pCluster) at step (3). During the 
synthesis of pCluster, a cationic polymer PLL (200 × 10−6 m, 
pH 7.4) was added dropwise to the solution of pParticle. Self-
assembled pClusters with a spherical shape were formed within 
few minutes due to the interaction between the protonated 
amine group in PLL and the carboxyl group of CA and BBI. To 
obtain the most appropriate size and pH sensibility, we used 
Adv. Funct. Mater. 2019, 29, 1807736
Figure 1. Schematic depiction for synthesis and function of pCluster.
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Figure 2. Preparation and characterization of pCluster. A) Schematic depiction for the three-step synthesis of pCluster. B) TEM image of p(BBI-SH-Au+), pre-
senting an irregular amorphous form. C) FTIR spectra of free peptide (BBI-SH) and Au–BBI polymeric structure (p(BBI-S-Au1+)). D) Molecular weight distribution 
of the [BBI-S-Au+]n polymers measured by the Mark–Houwink–Sakurada method, which uses empirical constants to calculate the molecular weight from the diffu-
sion coefficient determined from the autocorrelation function of the scattered light (DLS). E) Molecular weight measured by ESI mass of the p(BBI-SH-Au+) species. 
F) TEM image of pParticle. G) HPLC analysis of the pParticle after a 4 h incubation with 10 × 10−3 m dithiothreitol (pH 6.5), 75% acetonitrile (25% water), or 8 m 
guanidine hydrochloride. pParticle was separated by separation, and the supernatant was detected by HPLC. H) Hydrodynamic distributions of pParticle, pCluster 
at pH 6.5, and pCluster at pH 7.4 measured by dynamic light scattering, showing that pParticle has a narrow size distribution, and pCluster has a size-switchable 
property responded to the acidic pH. I) Fourier transform infrared spectra of pCluster and Au-particle, demonstrating the correct chemical structures of pCluster.
www.afm-journal.dewww.advancedsciencenews.com
1807736 (5 of 15) © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
different ratios of CA:BBI to synthesize pCluster, and found 
that the ratio of CA:BBI = 2:1 was the most viable (Table S1, 
Supporting Information). Based on this ratio, we measured 
the size of pCluster by dynamic light scattering (DLS), and 
determined that its diameter was around 89.3 nm (Figure 2H), 
which is a feasible size for EPR effect. This was also supported 
by the TEM observation (Figure S4A, Supporting Informa-
tion). For comparison, we also prepared the BBI- and CA-free 
nanoparticle, termed Au-particle. As shown in Figure 1I, FTIR 
spectroscopy proved successful synthesis of pCluster as evi-
denced by characteristic absorbance given by BBI, CA, and PLL. 
In ultraviolet–visible spectra (Figure S4B, Supporting Informa-
tion), compared to the pParticle, a red shift of characteristic 
peak in pCluster curve from 540 to 555 nm could be observed, 
indicating the larger size of pCluster. Taken together, these 
results strongly support that peptide, CA, and PLL are success-
fully conjugated to pParticles.
In general, nanoparticles with the size from 60 to 100 nm 
always possess drawn-out blood circulation and tend to extrava-
sate across the faulty tumor vasculature but enrich at the vicinity 
of blood vessels rather than distribution in the dense tumor 
matrix.[23] Although pony-sized nanoparticles (<15 nm) can 
deeply penetrate into the tumor and extensively distribute in 
the tumor matrix, they have to suffer from the stochastic diffu-
sion into noncancerous tissue.[23] Thus, to obtain tumor- specific 
extravasation, pCluster is supposed to maintain the large 
size in the circulation, while will transform to small size in 
the tumor acid microenvironment. To prove it, pClusters were 
incubated in the tumor-acidity mimic buffer (10 × 10−3 m PBS 
at pH 6.5) for 4 h, following the measurement of surface 
charge, hydrated particle size, and TEM morphology. Expect-
edly, the ZETA potential of pClusters reversed from −4.7 mV 
at pH 7.4 to 30.6 mV at pH 6.5 (Figure S4C, Supporting Infor-
mation), which was probably ascribed to the protonation of 
CA and BBI-SH (Figure S4D, Supporting Information). Aided 
by this charge reversal, pCluster disassembled into small 
nanoparticles with hydrated diameter of 10.8 nm (Figure 1H), 
which was in line with the TEM image (Figure S4A, Supporting 
Information).
The pH-responded pClusters were also sensitive to the 
elevated intracellular redox milieu, which would endow them 
with an intracellularly glutathione (GSH)-triggered drug 
release. To verify it, the high-performance liquid chromatog-
raphy (HPLC) was used to monitor drug release behaviors 
after incubation with three kinds of conditions: 1) 10 × 10−3 m  
PBS at pH 7.4, to mimic normal physiological environment; 
2) 10 × 10−3 m PBS at pH 6.5, to mimic acidic TME; and 
3) 10 × 10−3 m PBS at pH 6.5 containing 10 × 10−3 m GSH, 
to mimic intracellular reductive environment at tumor sites. 
After a 4 h incubation at pH 7.4, pCluster maintained its 
integrity and stability with <10% CA and <1% BBI-SH release 
(Figure S4E, Supporting Information). Adjusting pH to 6.5 
resulted in the partial CA release (<30% after 4 h), whereas 
no obvious BBI-SH release was observed under this condition 
(Figure S4E, Supporting Information). In a sharp contrast, 
when pClusters were incubated in intracellular redox envi-
ronment mimic solution, nearly all of the BBI and CA were 
totally released within an additional 4 h (Figure S4E, Sup-
porting Information).
2.3. Tumor-Specific Accumulation and TME-Triggered  
Cellular Uptake of pClusters
Small nanoparticles with positive charge can electrostatically 
attract to the negatively charged cell membrane, thereby trig-
gering cellular internalization.[24] By contrast, large negatively 
charged particles always suffer from the steric hindrance and 
charge repulsion, resulting in the failure of cellular inter-
nalization.[25] Given the size-convertible and charge-reversible 
behaviors of pClusters in response to the acidity (Figure 2H 
and Figure S4D, Supporting Information), the TME switches 
the pCluster from cellular rejection to cellular internaliza-
tion (Figure 3A). To prove it, pClusters were labelled with 
Texas Red, and their cellular internalization was evaluated in 
Hep3B and HCT116 cells. At pH 7.4, pClusters showed very 
low intracellular fluorescence in both Hep3B and HCT116 cells 
(Figure 3B), while cellular internalization was dramatically 
increased in these cells when pClusters were incubated at pH 6.5 
(Figure 3B). These results were proved again by quantitative 
flow cytometry (Figure 3C). To determine cellular internalization 
pathway, HCT116 cells were first coincubated with fluorescein 
isothiocyanate (FITC)-labeled pClusters at 37 or 4 °C (pH 6.5) 
for 4 h. The results showed that 4 °C incubation completely 
suppressed cellular internalization of pClusters (Figure S5A,B, 
Supporting Information), suggesting their cellular uptake 
is mediated by a adenosine triphosphate (ATP)-dependent 
pathway. Next, two specific inhibitors of micropinocytosis, Ami-
loride (targeting to cytoskeleton) and cytochalasin D (targeting 
to actin), were used to pretreat HCT116 cells. As expected, 
both of them abolished cellular internalization of pClusters 
(Figure S5C,D, Supporting Information), further demonstrating 
that pH-responded pCluster can effectively enter cancer cells 
as a result of micropinocytosis. Collectively, these findings 
indicate that pH-responded pCluster internalizes into cells via 
ATP-dependent micropinocytosis pathway.
Besides, small size of pH-responded pClusters is supposed 
to be in favor of the penetration and distribution in the tumor 
site. To verify this, tumor masses were isolated and incubated 
with FITC-labeled pCluster at pH 7.4 or 6.5 for 4 h. After 
fully washing, tumor masses were observed under fluores-
cence microscope. The results showed that fluorescence could 
only be detected in the internal area of tumor mass at pH 6.5, 
while almost did not observe fluorescence signal in intratu-
moral region at pH 7.4 (Figure S6, Supporting Information), 
indicating that small nanoparticles are favorable for tumor 
penetration and distribution.
More importantly, combined TME response with inherent 
EPR effect, pClusters could selectively enrich in the tumor 
sites. Via EPR effect, nanoparticles <150 nm can extravasate 
from the defective “leaky” tumor vasculature and accumulate 
in cancer cells.[25] In addition, ineffective lymphatic drainage is 
always accompanied by the increased tumor volume, resulting 
in the subsequently promoting nanoparticles retention.[26] 
Thus, to assess biodistributions of pClusters and pParticles 
in healthy organs and tumor, near-infrared fluorophore Texas 
Red was conjugated to pClusters and pParticles. As shown in 
Figure 3D, compared to pParticles, pClusters exhibited a higher 
accumulation at the tumor site 12 h after injection relative to 
other organs. Through further analyzing this fluorescence 
Adv. Funct. Mater. 2019, 29, 1807736
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distribution, we found that all ratios of tumor to noncancerous 
organ for pClusters were statistically significantly higher than 
that for pParticles (Figure 3E), indicating that pH-sensitive 
properties improved tumor specificity of pClusters. Biodistribu-
tions of pClusters were also examined at 2 and 6 h postinjec-
tion (Figure 3F). As shown in Figure 2G, all ratios of tumor 
Adv. Funct. Mater. 2019, 29, 1807736
Figure 3. High tumor selectivity of pCluster. A) Schematic depiction for tumor targeting of pCluster. B) Confocal laser scanning microscope (CLSM) 
images of HCT116 and Hep3B cells after a 6 h incubation with pCluster (20 µg mL−1) at pH 7.4 or pH 6.5, all images were taken under the same exciting 
light and detector gain (scale bar: 60 µm). C) Cellular uptake of pCluster responded to acidic pH by flow cytometry analysis. D) Ex vivo fluorescent 
images of tumors and major organs from pParticle- and pCluster-treated mice at 12 h postinjection. He, heart; Li, liver; Sp, spleen; Lu, lung; Ki, kidneys; 
Tu, tumor; Br, Brain. E) Tumor-to-background (normal organ or tissue) ratios for pParticle and pCluster at 12 h postinjection. pCluster showed much 
better tumor selectivity than pParticle (n = 3, mean ± s.d.). F) Ex vivo fluorescent images of tumors and major organs from pCluster treated mice at 
2 and 6 h postinjection. G) Tumor-to-background (normal organ or tissue) ratios for pCluster at 2 and 6 h postinjection. The latter showed significantly 
better tumor selectivity than the former (n = 3, mean ± s.d.). p values were calculated by t-test (*p < 0.05; **p < 0.01).
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to noncancerous organ at 6 h postinjection were significantly 
higher than the ratios at 2 h postinjection, further supporting 
pClusters with high targeting ability to tumor. Notably, we 
almost did not observe the accumulation of pClusters in liver 
and kidney at 12 postinjection (Figure 3D), demonstrating 
pClusters with high metabolizability rate.
2.4. pCluster Potently Inhibits Tumor Growth In Vitro and In Vivo
Bcl9 is highly expressed in human cancer cells, and facilitates 
β-catenin entry into the nucleus, promoting tumor progression 
by activating Wnt pathway.[27] By our design, BBI can efficiently 
inhibit this process via blocking the interaction between Bcl9 
and β-catenin (Figure S7A, Supporting Information). In addi-
tion to being a reductant for pCluster synthesis, CA is also 
an effective small molecule inhibitor targeting the Wnt sign-
aling through inducing cytoplasmic β-catenin degradation 
(Figure S7A, Supporting Information).[28] Thus, pCluster is a 
multiple stimuli-responsive synthetic cytostatic with two dif-
ferent functions to block the Wnt/β-catenin pathway in cancer 
cells (Figure 4A). First, the thiazolyl blue (MTT) assay was per-
formed to assess the effect of pClusters on the proliferation of 
three Wnt-activated cancer cell lines: Hep3B (human hepatoma 
cell line), HCT116 (human colorectal cell line), and F16B10 
(murine melanoma cell line) cells. As shown in Figure 4B and 
Figure S7B–D (Supporting Information), pCluster, pParticle, 
and CA inhibited the proliferation of these cells in a dose-
dependent manner, while Au-Cluster as a control almost did 
not affect cell proliferation. Notably, pCluster was more potent 
than CA and pParticle in these three Wnt-activated cancer cell 
lines (Figure S7B–D, Supporting Information), while it did not 
show any advantage of inhibitory proliferation in a Wnt-latent 
lung adenocarcinoma cell line A549 compared to pParticle 
(Figure S7E, Supporting Information). There is evidence dem-
onstrating that blockade of β-catenin–Bcl9 interaction by CA 
or peptide inhibitors can result in the instability of β-catenin 
and subsequent degradation of β-catenin.[20,28] Expectedly, our 
data showed that β-catenin was significantly decreased upon 
treatment of pCluster, pParticle, and 10 × 10−6 m CA relative 
to the control in both Hep3B and HCT116 cells (Figure 4C 
and Figure S8, Supporting Information), indicating the suc-
cessful disruption of β-catenin–BCL9 interaction. In line with 
β-catenin, Cyclin D, a downstream target of the Wnt/β-catenin 
signaling pathway,[29] was significantly down-regulated by these 
β-catenin/Bcl9 inhibitors, further proving the bioactivity of 
these β-catenin antagonists. In addition, given that Cyclin D 
acts as a cell cycle regulatory factor, we expectedly found that 
pParticle, CA, and pCluster significantly induced G0/G1 phase 
arrest in Hep3B and HCT116 cells but not A549 cells compared 
to Au-Cluster, particularly pCluster (Figure 4D and Figure S9, 
Supporting Information).
To test in vivo antitumor activity of pCluster, nude mice 
bearing Hep3B xenograft tumors were used to investigate ther-
apeutic efficacy of our nanoclusters. As shown in Figure 3E, 
tumor volume in the PBS-treated (control) group increased 
rapidly during the 12-day treatment, while CA and pParticle 
without CA moderately inhibited tumor growth. By a sharp con-
trast, pParticle with CA displayed much higher tumor-inhibitory 
effect than CA alone or pParticle without CA, indicating that 
combination of CA and BBI induces synthetic cytostatic effect 
on tumor growth. Importantly, pCluster exhibited better anti-
tumor activity than pParticle (Figure 4E), further demonstrating 
the superiority of TME-responsive behaviors. At the 12th day, 
xenograft tumors were isolated and weighed (Figure 4F,G). Sta-
tistical data on tumor weight further supported the above con-
clusions. Next, we performed the immunohistochemical (IHC) 
assay to measure the levels of Ki67 (a well-known prolifera-
tive marker) and evaluate the proliferative ability of tumor. As 
shown in Figure 4H and Figure S10 (Supporting Information), 
it can be found that the percentage of Ki67-positive cells in the 
pCluster-treated tumors was much lower than that in the other 
tumors. In addition, we expectedly found a significant decrease 
in β-catenin levels in the pCluster-treated tumors compared 
to the other tumors by IHC assay (Figure 4I). Meanwhile, we 
also found that pCluster treatment obviously decreased nuclear 
β-catenin and increased membranous β-catenin, especially at 
cell junctions (Figure S10, Supporting Information). Accord-
ingly, there was a significant decrease in Cyclin D levels in the 
pCluster-treated tumors relative to the other tumors (Figure 4J). 
Collectively, as an efficient inhibitor of the Wnt signaling, 
pCluster extremely has the potential to be an applicable nano-
therapeutic for anticancer therapy.
2.5. pCluster Maintains a Highly Favorable Biosafety Profile
In the last 30 years, although there have been many ground-
breaking discoveries of the conserved Wnt signaling pathway,[30] 
none of Wnt-targeted therapeutic has yet been approved for 
clinical application.[15] The major cause is severe side effects 
from these Wnt inhibitors because blockade of this pathway 
can also impair physiological functions of normal cells, such 
as tissue homeostasis and repair.[15] Thus, it will require an 
accurate act, by which the Wnt signaling can be precisely 
abrogated at the tumor sites, while did not interfere its physi-
ological roles in normal cells. To this end, a double-targeting 
strategy was adopted in our design to guarantee tumor enrich-
ment other than normal organs (Figure 5A). As mentioned 
above, aided by the EPR effect and TME response, pClusters 
can specifically accumulate in the tumor site, thereby achieving 
a switchable cellular uptake in response to TME. Thus, this 
two-level- targeting strategy will greatly reduce the risk of side 
effects from Wnt inhibitors.
To validate the biosafety of pCluster, we first determined the 
effect of pCluster on the viability of the peripheral blood mono-
nuclear cells (PBMCs). Expectedly, we did not observe cytotoxic 
effect of pCluster on PBMCs at pH 6.5 and pH 7.4 (Figure S11, 
Supporting Information). To further determine the biosafety 
of pCluster, a series of biosafety assessments were performed 
during and after pCluster treatment. During administration, 
pParticle- and CA-treated mice suffered a series of side effects 
including severe hemocytosis and organic damage, while 
pCluster-treated mice remained in perfect health (Figure 5B). 
In details, pParticle- and CA-mice showed low levels of white 
blood cells and platelets (Figure 5C,D), and rapid loss of body 
weight relative to control or healthy mice (Figure 5E). In addi-
tion, CA and pParticle treatment resulted in changes of liver 
Adv. Funct. Mater. 2019, 29, 1807736
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Figure 4. Antitumor activity of pCluster. A) Schematic depiction of GSH-responded drug release and biological functions of pCluster. B) Effects of 
pCluster, pParticle, Au-Cluster, and carnosic acid (CA) on the growth of Hep3B, HCT116, B16F10, and A549 cells measured by MTS assay (mean ± s.d., 
n = 4). C) Western blot analysis was performed to monitor the level of Cyclin D and β-catenin in Hep3B cells with the indicated treatments. All results 
were performed in triplicate and normalized by the loading control, β-actin. D) Cell cycle distributions were analyzed by flow cytometry in Hep3B cells 
with the indicated treatments for 24 h (n = 3, mean ± s.d.). E) Tumor growth curve of volume according time during the administration (mean ± s.d., 
n = 5). Statistically significant differences were judged by Kruskal–Wallis test. F) Photographs and G) weight of tumors collected from mice after 12-day 
administration. Immunohistochemical (IHC) scores of intratumoral protein levels of H) Ki67, I) β-catenin, and J) Cyclin D. p values were calculated 
by t-test (*p < 0.05; **p < 0.01; ***p < 0.001).
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function and pathology (Figure 5F–J), the symptoms of acute 
kidney inflammation and glomerular lesions (Figure 5K–M), 
and spleen failure (Figure S12A,B, Supporting Information). 
By a sharp contrast, none of these hemocytosis and organic 
damage was observed in all of the pCluster-treated mice 
(Figure 5B–M), indicating the favorable biological reliability of 
pCluster. Notably, all pCluster-, pParticle-, and CA-treated mice 
did not encounter common side effects of chemotherapeutics, 
Adv. Funct. Mater. 2019, 29, 1807736
Figure 5. Biosafety evaluation of pCluster. A) Schematic diagram for the safety of cancer therapy benefitted from three-level target identification of 
pCluster. B) Disease diagnosis in mice with the indicated treatments. C,D) The count of white blood cells (WBCs) and thrombocyte in mice with the 
indicated treatments. E) The time course of animal weight in each group with the indicated treatments. F–H) The activities of three liver enzymes related 
to liver function in mice with the indicated treatments. AST: aspartate aminotransferase; ALT: alanine transaminase; ALP: alkaline phosphatase. I) The 
changes in liver weight of mice with the indicated treatments. J) The representative images of H&E-stained liver sections in mice with the indicated 
treatments (scale bar: 50 µm). K,L) The measurement of renal function indicators in mice with the indicated treatments. CRE: serum creatinine; BUN: 
blood urea nitrogen. M) The representative images of H&E-stained kidney sections in mice with the indicated treatments (scale bar: 50 µm). Data 
were presented as mean ± s.e. p values were calculated by t-test (*p < 0.05; **p < 0.01; ***p < 0.001).
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including heart failure (Figure S12C,D, Supporting Informa-
tion), acute sepsis (Figure S13A,B, Supporting Information), 
or allergic lung resistance (Figure S13C,D, Supporting Infor-
mation). Altogether, our data demonstrate that pCluster is 
avirulent enough for clinical use.
2.6. pCluster Effectively Suppresses Tumor Metastasis
Tumor metastasis is a major determinant of poor patient sur-
vival, accounting for 90% of cancer-related death.[31] The Wnt/β-
catenin signaling pathway is always hyperactivated during 
tumor metastasis.[32] Upon activated Wnt signaling, β-catenin 
can be shuttled by Bcl9 into nucleus to promote tumor cell 
proliferation and metastasis.[33] With our design, pCluster can 
effectively block the activity of Wnt/β-catenin pathway, thereby 
suppressing tumor metastasis (Figure 6A). Cell migration and 
invasion are two key properties associated with tumor metas-
tasis. Therefore, we first evaluated the effect of pCluster on in 
vitro migration and invasion abilities of HCT116 and F16B10 
cells. Upon a 24 h incubation with 100 × 10−9 m pClusters, the 
number of migrating/invading cells were significantly less than 
the control (Figure 6B,C) in both of these two cell lines.
To determine antimetastasis activity of pCluster in vivo, B16F10 
cells (5 × 104 per mouse) were injected into the caudal vein of C57 
mice to construct lung metastasis model. From the 4th day after 
cell injection, mice were consecutively administered pClusters for 
14 days at a dose of 1 mg per kg per two days. After administra-
tion, lung metastasis was significantly inhibited upon pCluster by 
either intravenous injection or intraperitoneal injection compared 
to the control (Figure S14, Supporting Information). To further 
determine the effect of pCluster on the metastatic tumors at both 
tissue and protein levels, 5 × 105 B16F10 cells were injected into 
the caudal vein of each mice to cause more severe pulmonary 
metastasis. As shown in Figure 6D,E, we indeed found more 
metastatic nodules in the lung of control mice, and demonstrated 
that lung metastasis of B16F10 cells was dramatically inhibited 
by pClusters. This was also supported by the data from the H&E-
stained tissue sections (Figure 6F) and metastatic area analysis 
(Figure 6G). To elucidate the mechanism, the levels of β-catenin 
and its downstream metastasis-related proteins such as CD133 
and matrix metallopeptidase 9 (MMP9) were measured by the 
IHC assay. In general, β-catenin positively feedbacks to CD133 
in tumorigenesis, thereby inhibiting cell differentiation and sub-
sequently showing the properties of cancer stem cells.[34] In addi-
tion, the Wnt/β-catenin cascade can also regulate the expression 
of MMP9, which is closely associated with tumor metastasis.[35] 
As expected, the expression of β-catenin, CD133, and MMP9 
in metastatic lesions was decreased upon pCluster treatment 
in Figure 6H. Collectively, our data demonstrate that pClusters 
strongly inhibit tumor metastasis in vitro and in vivo through 
blocking Wnt/β-catenin signaling.
2.7. pCluster Synergizes the PD-L1 Checkpoint Blockade 
Immunotherapy
PD-1/PD-L1 signaling pathway induces the cytotoxic T lympho-
cytes (CTL) exhaustion, as a result of tumor immune evasion.[36] 
In recent years, PD-1/PD-L1 checkpoint-blockade strategies 
have been approved to enhance antitumor immunities by inhib-
iting CTL exhaustion;[37] however, only a fraction of patients 
respond to this treatment. There is evidence showing that treat-
ment outcome is merely achieved in cancerous persons with a 
high number of infiltrated CTL cells within the TME.[38] Unfor-
tunately, intratumoral active Wnt/β-catenin cascade can block 
T-cell infiltration, thereby resulting in the resistance to PD-1/
PD-L1-derived immunotherapy.[39] Encouraged by potent inhi-
bition of Wnt/β-catenin signaling by pCluster, we hypothesize 
that pCluster treatment may eliminate the resistance and has a 
synergistic effect with PD-L1 checkpoint blockade (Figure 7A, 
left panel).
To prove this, a MC38 homografting colon cancer model 
was established at the flank of normal C57 mice (Figure 7A, 
right panel). After the tumors reaching 50–80 mm3, all mice 
were randomly divided into four groups (five mice per group): 
1) PBS (Control); 2) pCluster treatment; 3) PD1/PDL1 inhibitor 
treatment; 4) pCluster plus PD1/PDL1 inhibitor (PPI) treat-
ment. As expected, combined treatment of pCluster and PPI 
synergistically inhibited tumor growth compared to PPI treat-
ment alone (Figure 7B–D). This was also supported by the 
results of Ki67-staining in the tumors with the indicated treat-
ments (Figure 7E and F). In addition, we also found that the 
levels of β-catenin were significantly decreased upon pCluster 
treatment alone and combined treatment relative to the control 
(Figure 7G,H), indicating successful blockade of Wnt/β-catenin 
signaling. Importantly, the inhibition of Wnt/β-catenin pathway 
caused a significant decrease in tumor cell density (Figure 7I,J), 
thereby eliminating the barrier of CTL infiltration. Next, we 
attempted to confirm the elicitation of CTL (CD8+ T-cell) infil-
tration by pCluster treatment. As shown in Figure 7K,L, the 
CTL was remarkably enriched in the tumors with combined 
therapy (group 4) compared to those with PPI monotherapy 
(group 3). Taken together, our data demonstrate that pCluster 
can reverse the immunosuppression caused by activated 
Wnt/β-catenin signaling to synergize the PD-1/PD-L1 check-
point-blockade therapies, ultimately improving the efficacy of 
anticancer therapy.
3. Discussion
Human diseases including malignancies are generally caused 
by aberrant PPIs, either through the dysfunction of essential 
interactions or the structural variation of protein complex.[40] 
The PPI modulation can correct aberrant function of the 
protein complex, thereby paving the way to develop clinical 
diagnostics and therapeutics.[6] Compared to the interfer-
ence of gene transcription by siRNA, PPI modulation can 
keep the normal function of target protein other than destroy 
the whole protein, thereby greatly reducing possible side 
effects from the deficiency of target protein. Considering 
that β-catenin is required for many normal physiological 
processes in especial of stem cell proliferation and differ-
entiation,[30] thus disturbing β-catenin expression at tran-
scriptional levels will result in the maladjustment of these 
β-catenin-dependent physiological processes. However, the 
interaction between β-catenin and Bcl9 specifically occurred 
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in cancer cell,[41] thus modulating β-catenin–Bcl9 interac-
tion other than disturbing β-catenin transcription would be 
a class of safe anticancer therapy. However, it is extremely 
difficult to target β-catenin–Bcl9 interaction because of their 
high, flat, and featureless surface area. While small molecule 
inhibitors have been proven successful in targeting enzymes, 
receptors, and ion channels for clinical applications, they are 
not applicable to modulate PPIs in general because of their 
limited size.
Peptides, aided by the large interacting surfaces of diverse 
topological structure, serve as ideal candidates to modulate 
PPIs.[4] Moreover, it is viable and convenient to design a pep-
tide inhibitor derived from the linear sequence. However, three 
pharmacological obstacles still hinder their clinical application, 
Figure 6. Inhibitory effect of pCluster on tumor metastasis. A) Schematic diagram of pCluster suppressing tumor distant metastasis. B,C) The rep-
resentative pictures of migrated/invaded cells (left panels). Histograms, corresponding to left panels, show means ± s.d. of cell numbers from three 
independent assays (right panels). D) The representative photographs of lungs taken 15 days after injection of B16F10 cells. Macroscopic analysis of 
the lungs confirmed that pCluster decreased the lung colonization by B16F10 cells. E) The number of superficial macroscopic metastases in the lungs 
(n = 5). F) The representative photographs of the H&E-stained tissue sections of pulmonary metastases. G) The percentage of pulmonary metastatic 
area analyzed from (F) (n = 5). H) The representative IHC staining of β-catenin, CD133, and MMP9 for three serial sections from pulmonary metastasis 
tumors (scale bar: 100 µm). p values were calculated by t-test (***p < 0.001).
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Figure 7. Synergistic effect of pCluster on the PD-L1 checkpoint blockade immunotherapy. A) The proposed mechanism of pCluster synergizing anti-
PD-L1 immunotherapy. B) Tumor growth curves in mice with the indicated treatments. A statistical analysis was performed using a nonparametric 
Kruskal–Wallis test. Data were presented as mean ± s.e. (n = 5). C) Photographs and D) weight of xenograft tumors collected from mice with the 
indicated treatments. E) Representative IHC staining and F) IHC score for Ki67 in tumor tissues from mice with the indicated treatments (scale bar: 
50 µm). G) Representative IHC staining and H) IHC score for β-catenin in tumor tissues from mice with the indicated treatments (scale bar: 50 µm). 
I) Representative H&E staining and J) tumor cell density of tumor tissues from mice with the indicated treatments (scale bar: 50 µm). K) Representa-
tive IHC staining and L) IHC score for CD8 positive T cells in tumor tissues from mice with the indicated treatments (scale bar: 50 µm). p values were 
calculated by t-test (*p < 0.05; **p < 0.01; ***p < 0.001).
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including: 1) short half-life of blood circulation, 2) horrible cel-
lular internalization, and 3) limited tumor specificity.[4,5] To 
overcome these bottlenecks, we successfully developed a clini-
cally practicable strategy through assembling therapeutic pep-
tide and gold ion into a TME-responsive polymeric Au–peptide 
nanocluster. Synergized with EPR effects, TME responsiveness 
can endow delivery system with high targeting ability to tumor. 
During the circulation and at the healthy organ, the large size 
and negative charge of pCluster can impede its tissue infil-
tration and cellular uptake. By contrast, responding to acidic 
TME, pCluster can disassemble into small positively charged 
nanoparticles, which is favorable of neoplastic retention and 
cellular internalization. In this proof-of-concept study, we spe-
cifically delivered these nanoclusters into the tumor cells, and 
demonstrated that they potently inhibited tumor growth and 
metastasis, and synergized the efficacy of PD-L1 inhibitor in 
several animal models. Compared to exciting strategies such as 
sidechain-stapling, backbone-cyclizing, D-enantiomerization, 
and liposome encapsulation, the present strategy can easily 
and rapidly turn a peptide-derived PPI inhibitor into a tumor-
specific therapeutic agent instead of complicated design and 
priori assess. Considering that peptide is easy to modify, this 
strategy directly endows the therapeutic peptides whose pKI is 
at neutral, with TME-responsiveness, which allows the peptides 
to selectively reach and penetrate the tumor sites with very low 
toxicity. More importantly, compared to conventional method to 
link peptides to the surface of nanoparticles, pParticles can take 
full advantage of the whole volume to load the peptide cargo, 
thereby fundamentally solving the problem of low cargo loading 
and the aggregation resulting from the peptide conjugation.
Given that pathologic role of the β-catenin in a broad range of 
human cancers and preventing antitumor immunity,[20,39] it has 
become a potential pharmacologic target. However, β-catenin 
participates in many important homeostatic functions,[42] thus 
it will be a pressing challenge to simultaneously achieve high 
anticancer activity and selectivity. Although some therapeutics 
have been demonstrated to successfully inhibit tumor growth 
through blocking the Wnt pathway; however, severe side effects 
such as bone marrow hypoplasia and anemia are unfortu-
nately observed in experimental animals. Profited from the 
switch of cytomembrane penetration in response to acidic TME 
(Figure 3B,C), pCluster can penetrate cytomembrane entering 
cellular inner only at the tumor sites but not in healthy organs 
such as liver and kidney. Thus, although there exists the accu-
mulation of pClusters in liver, the switch of cytomembrane 
penetration can keep the healthy cells safe, as supported by our 
data that side effects were not observed in mice treated with 
pClusters. Thus, this proof-of-concept study highlights clinical 
translation potential of this peptide-derived anticancer strategy, 
thereby achieving a therapeutic window to combat Wnt-driven 
cancers.
4. Conclusions
In summary, the data presented here provide compelling evi-
dence that this novel TME-responsive peptide-derived clustered 
nanohybrid (pCluster) is advantageous in delivering therapeutic 
peptides into tumor sites and overcoming important obstacles 
to the application of anticancer peptides. Through this strategy, 
nanoparticles formed by copolymerized Au–peptide can self-
assemble into pH-responsive higher-order pCluster, and subse-
quently disintegrate into Au–peptide nanoparticles only in the 
tumor sites, thereby achieving efficient tumor-specific cellular 
uptake of peptide cargo. Our data demonstrate that pClusters 
potently inhibit tumor growth and metastasis, and synergize the 
PD-L1 checkpoint blockade immunotherapy through impairing 
Wnt/β-catenin cascade. With superior biosafety, pCluster has 
shown great potential in clinical translation as Wnt/β-catenin 
signaling inhibitor for anticancer peptide therapeutics. More 
importantly, this viable general strategy will likely have a broad 
impact on the development of peptide-based nanomedicine for 
cancer therapy.
5. Experimental Section
Fabrication of pParticle and pCluster: The tetra chloroauric acid 
aqueous solution of HAuCl4 · XH2O (0.01 m, 1 mL) was mixed with the 
aqueous solution of BBI-SH (250 × 10−6 m, 8.5 mL). By using 6 m NaOH, 
the pH of the mixture solution was adjusted between 6.0 and 7.0. A 
total volume of 500 µL solution containing freshly prepared 0.1 m VC 
and 0.1 m CA was added with stirring. The pParticles were then prepared 
after 1 h reaction at 25 °C. Next, the excess reactants were eliminated by 
dialysis tubing (cutoff, 10 KDa). To synthesize pCluster, 500 µL cationic 
polymer PLL solution (Mw: 20 kDa, 2 × 10−3 m, pH 7.4) was added 
dropwise to the above solution of pParticle. The collection of nano-gold 
cluster fraction was concentrated by centrifugal filtration (molecular 
weight cut off (MWCO) 50 kDa, Millipore Amico Ultra). After that, 
pParticles and pClusters were freeze-dried for subsequent experiments.
Quantification of Drug Loading and GSH-Responded Drug Release: First, 
the PBS buffer (pH 7.4) was prepared, containing GuHCL (6 m) and DTT 
(1 m). The prepared buffer can break the bond between the BBI-SH and 
gold atoms. For quantification of drug loading, pClusters or pParticles 
were dissolved in the above prepared PBS buffer (pH 7.4), and the 
amounts of released peptides or CA were then quantified using HPLC. 
As for the test of GSH-responded drug release, pClusters or pParticles 
were first added into PBS buffer (pH 7.4) containing 10 × 10−3 m  
glutathione. After 1 h incubation at room temperature, pClusters or 
pParticles were removed by 10 000 g centrifuge. The supernatants were 
authenticated by ESI mass and quantified by HPLC.
In Vivo Biodistribution Analysis: HCT116 cells (4 × 106 cells per site) 
were subcutaneously injected into the hip of four- to five-weeks-old male 
athymic nude mice. Four weeks after inoculation, 200 µL Texas Red-
labelled pClusters or pParticles (1 mg mL−1) were injected into the mice 
via intraperitoneal injection. We took the ex vivo images of mice using 
the IVIS Spectrum In Vivo Imaging System with an excitation wavelength 
of 620 nm. According to the experimental plan, the mice were killed 
humanely at predetermined times, and different organs and tumor 
were then obtained from each mouse. The fluorescence intensities of all 
organs and tumor were analyzed by the IVIS Spectrum In Vivo Imaging 
System.
Xenograft Tumor Model: According to Institution Guidelines, we 
designed all animal experiments and obtained the approvement from 
the Laboratory Animal Center of Xi’an Jiaotong University. The xenograft 
tumor model was similarly established as mentioned above.[8] When the 
average tumor volume reached ≈50 mm3, the mice bearing xenograft 
tumors were then randomly divided into different groups (five mice 
per group), and the treatment was begun. pCluster, pParticle, pParticle 
without CA, and CA were administered at 1 mg kg−1 on d 2, 4, 6, and 8, 
with PBS as a negative control. Tumor volume was calculated, 
and H&E or immunohistochemical staining was performed as described 
previously.[43] In addition, all exploration on drug toxicity was followed by 
the standard clinical laboratory procedures as our previous reports.[44]
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Tail Vein Metastasis Model: We collected and resuspended B16F10 cells 
in 1640 medium without fetal bovine serum (FBS). Different number of 
cells were then injected into the vein tail of C57BL/6 mice. The detailed 
dosages were as follows: 5 × 104 cells per 0.2 mL for comparing therapy 
efficacy of different route of administration, and 5 × 105 cells per 0.2 mL 
for assessing inhibitory effect of pCluster on tumor metastasis. 10 mice 
were randomly and equally divided into two groups: the PSB-treated 
(Control) groups and pCluster-treated groups. pCluster injection was 
started 3th day after cell injection. The pCluster-treated mice were 
intraperitoneally administrated with 1 mg kg−1 pCluster every other two 
days for consecutive 1 week (4 times injection). The mice in control 
group were administrated with an equal volume of PBS. The mice 
were euthanized on the 10th day to compare therapy efficacy between 
i.v and i.p. administration of pCluster, while the mice were euthanized 
on the 14th day to evaluate the effect of pCluster on tumor metastasis. 
The lungs were separated and photographed, and then the numbers of 
metastatic nodules on the surface of lungs were counted. Following this, 
paraffin sections of lung tissue were prepared for H&E staining and IHC 
staining of β-catenin, MMP9, and CD133.
Synergistic Effect of pCluster on PD-L1 Therapy in Animal Model: 
First, 5 × 105 MC38 cells were subcutaneously injected into the flank 
of C57BL/6 mice. After about two weeks, tumor volume of each mice 
reached ≈100 mm3. Mice were divided into four groups randomly (five 
mice per group): PBS control; pCluster; PPI; PPI + pCluster. The PPIs 
(2.5 mg kg−1) were intraperitoneally injected into animals every other 
day (days 0, 2, 4, and 6) for a total of four injections as previously 
described,[45] by which this dose of 2.5 mg kg−1 can inhibit tumor growth 
at a certain degree rather than being too high to mask antitumor effect 
of pCluster. The dosage of pCluster was consistent with the pCluster 
dosage (1 mg kg−1) used in the nude mouse model (Figure 4) and 
the metastasis model (Figure 6), and pClusters (1 mg kg−1) were 
intraperitoneally injected into animals at days 1, 3, and 5. Tumor sizes 
were monitored every day. All mice were euthanized at day 11, and the 
tumors were resected, photographed, and weighted. All tissue samples 
were then prepared for H&E staining and IHC staining of β-catenin, 
Ki67, and CD8 as described previously.[8]
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